skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 9,189  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports
Material Type:
Article
Add to My Research

Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports

Medicine (Baltimore), 2021-03, Vol.100 (10), p.e25046-e25046 [Peer Reviewed Journal]

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. ;Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000025046 ;PMID: 33725888

Full text available

2
Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China
Material Type:
Article
Add to My Research

Diagnostic and therapeutic value of progastrin‐releasing peptide on small‐cell lung cancer: A Single‐Center Experience in China

Journal of cellular and molecular medicine, 2018-09, Vol.22 (9), p.4328-4334 [Peer Reviewed Journal]

2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. ;2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.13722 ;PMID: 29989303

Full text available

3
The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
Material Type:
Article
Add to My Research

The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery

Molecular oncology, 2019-05, Vol.13 (5), p.1166-1179 [Peer Reviewed Journal]

2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. ;COPYRIGHT 2019 John Wiley & Sons, Inc. ;2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;info:eu-repo/semantics/openAccess ;ISSN: 1574-7891 ;EISSN: 1878-0261 ;DOI: 10.1002/1878-0261.12475 ;PMID: 30854794

Full text available

4
Nintedanib reduces ventilation‐augmented bleomycin‐induced epithelial–mesenchymal transition and lung fibrosis through suppression of the Src pathway
Material Type:
Article
Add to My Research

Nintedanib reduces ventilation‐augmented bleomycin‐induced epithelial–mesenchymal transition and lung fibrosis through suppression of the Src pathway

Journal of cellular and molecular medicine, 2017-11, Vol.21 (11), p.2937-2949 [Peer Reviewed Journal]

2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. ;2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.13206 ;PMID: 28598023

Full text available

5
Metformin and tenovin‐6 synergistically induces apoptosis through LKB1‐independent SIRT1 down‐regulation in non‐small cell lung cancer cells
Material Type:
Article
Add to My Research

Metformin and tenovin‐6 synergistically induces apoptosis through LKB1‐independent SIRT1 down‐regulation in non‐small cell lung cancer cells

Journal of cellular and molecular medicine, 2019-04, Vol.23 (4), p.2872-2889 [Peer Reviewed Journal]

2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. ;2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.14194 ;PMID: 30710424

Full text available

6
Correlation of iodine uptake and perfusion parameters between dual-energy CT imaging and first-pass dual-input perfusion CT in lung cancer
Material Type:
Article
Add to My Research

Correlation of iodine uptake and perfusion parameters between dual-energy CT imaging and first-pass dual-input perfusion CT in lung cancer

Medicine (Baltimore), 2017-07, Vol.96 (28), p.e7479-e7479 [Peer Reviewed Journal]

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. 2017 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000007479 ;PMID: 28700488

Full text available

7
Circular RNA SMARCA5 may serve as a tumor suppressor in non‐small cell lung cancer
Material Type:
Article
Add to My Research

Circular RNA SMARCA5 may serve as a tumor suppressor in non‐small cell lung cancer

Journal of clinical laboratory analysis, 2020-05, Vol.34 (5), p.e23195-n/a [Peer Reviewed Journal]

2020 The Authors. Published by Wiley Periodicals, Inc. ;2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. ;2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0887-8013 ;EISSN: 1098-2825 ;DOI: 10.1002/jcla.23195 ;PMID: 31944395

Full text available

8
MiR-222-3p Promotes Cell Proliferation and Inhibits Apoptosis by Targeting PUMA (BBC3) in Non-Small Cell Lung Cancer
Material Type:
Article
Add to My Research

MiR-222-3p Promotes Cell Proliferation and Inhibits Apoptosis by Targeting PUMA (BBC3) in Non-Small Cell Lung Cancer

Technology in cancer research & treatment, 2020, Vol.19, p.1533033820922558-1533033820922558 [Peer Reviewed Journal]

The Author(s) 2020 ;The Author(s) 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 2020 SAGE Publications ;ISSN: 1533-0346 ;EISSN: 1533-0338 ;DOI: 10.1177/1533033820922558 ;PMID: 32588752

Full text available

9
Muscle mass and association to quality of life in non‐small cell lung cancer patients
Material Type:
Article
Add to My Research

Muscle mass and association to quality of life in non‐small cell lung cancer patients

Journal of cachexia, sarcopenia and muscle, 2017-10, Vol.8 (5), p.759-767 [Peer Reviewed Journal]

2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders ;2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. ;2017. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;info:eu-repo/semantics/openAccess ;ISSN: 2190-5991 ;ISSN: 2190-6009 ;EISSN: 2190-6009 ;DOI: 10.1002/jcsm.12206 ;PMID: 28493418

Full text available

10
IL‐6 promotes metastasis of non‐small‐cell lung cancer by up‐regulating TIM‐4 via NF‐κB
Material Type:
Article
Add to My Research

IL‐6 promotes metastasis of non‐small‐cell lung cancer by up‐regulating TIM‐4 via NF‐κB

Cell proliferation, 2020-03, Vol.53 (3), p.e12776-n/a [Peer Reviewed Journal]

2020 The Authors. Published by John Wiley & Sons Ltd. ;2020 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd. ;2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0960-7722 ;EISSN: 1365-2184 ;DOI: 10.1111/cpr.12776 ;PMID: 32020709

Full text available

11
Long non‐coding RNAs in non‐small cell lung cancer as biomarkers and therapeutic targets
Material Type:
Article
Add to My Research

Long non‐coding RNAs in non‐small cell lung cancer as biomarkers and therapeutic targets

Journal of cellular and molecular medicine, 2014-12, Vol.18 (12), p.2425-2436 [Peer Reviewed Journal]

2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. ;Copyright © 2014 John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine ;2014. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. 2014 ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.12431 ;PMID: 25297942

Full text available

12
A novel circulating miRNA‐based signature for the early diagnosis and prognosis prediction of non–small‐cell lung cancer
Material Type:
Article
Add to My Research

A novel circulating miRNA‐based signature for the early diagnosis and prognosis prediction of non–small‐cell lung cancer

Journal of clinical laboratory analysis, 2020-11, Vol.34 (11), p.e23505-n/a [Peer Reviewed Journal]

2020 The Authors. published by Wiley Periodicals LLC ;2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. ;2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0887-8013 ;EISSN: 1098-2825 ;DOI: 10.1002/jcla.23505 ;PMID: 33463758

Full text available

13
A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer
Material Type:
Article
Add to My Research

A multi‐omic study reveals BTG2 as a reliable prognostic marker for early‐stage non‐small cell lung cancer

Molecular oncology, 2018-06, Vol.12 (6), p.913-924 [Peer Reviewed Journal]

2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. ;2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;info:eu-repo/semantics/openAccess ;ISSN: 1574-7891 ;EISSN: 1878-0261 ;DOI: 10.1002/1878-0261.12204 ;PMID: 29656435

Full text available

14
Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness via regulating the miR-587/bone morphogenetic protein 3 axis in lung adenocarcinoma
Material Type:
Article
Add to My Research

Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness via regulating the miR-587/bone morphogenetic protein 3 axis in lung adenocarcinoma

Human & experimental toxicology, 2022-01, Vol.41 [Peer Reviewed Journal]

The Author(s) 2022 ;ISSN: 0960-3271 ;EISSN: 1477-0903 ;DOI: 10.1177/09603271221138971

Digital Resources/Online E-Resources

15
Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer
Material Type:
Article
Add to My Research

Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer

Molecular oncology, 2022-01, Vol.16 (2), p.527-537 [Peer Reviewed Journal]

2021 The Authors. published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies ;2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. ;2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1574-7891 ;ISSN: 1878-0261 ;EISSN: 1878-0261 ;DOI: 10.1002/1878-0261.13116 ;PMID: 34653314

Full text available

16
Systematic construction and validation of an immune prognostic model for lung adenocarcinoma
Material Type:
Article
Add to My Research

Systematic construction and validation of an immune prognostic model for lung adenocarcinoma

Journal of cellular and molecular medicine, 2020-01, Vol.24 (2), p.1233-1244 [Peer Reviewed Journal]

2019 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd ;2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. ;2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.14719 ;PMID: 31779055

Full text available

17
Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD
Material Type:
Article
Add to My Research

Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD

Journal of cellular and molecular medicine, 2024-04, Vol.28 (8), p.e18282-n/a [Peer Reviewed Journal]

2024 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. ;2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. ;2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1582-1838 ;EISSN: 1582-4934 ;DOI: 10.1111/jcmm.18282 ;PMID: 38647237

Full text available

18
Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis
Material Type:
Article
Add to My Research

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis

Technology in cancer research & treatment, 2021, Vol.20, p.15330338211060202 [Peer Reviewed Journal]

The Author(s) 2021 ;The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 2021 SAGE Publications ;ISSN: 1533-0346 ;EISSN: 1533-0338 ;DOI: 10.1177/15330338211060202 ;PMID: 34825846

Full text available

19
Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS–mitochondrial fission–mitophagy axis
Material Type:
Article
Add to My Research

Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS–mitochondrial fission–mitophagy axis

Molecular oncology, 2021-08, Vol.15 (8), p.2084-2105 [Peer Reviewed Journal]

2021 The Authors. published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies ;2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. ;COPYRIGHT 2021 John Wiley & Sons, Inc. ;2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1574-7891 ;EISSN: 1878-0261 ;DOI: 10.1002/1878-0261.12936 ;PMID: 33675143

Full text available

20
PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer
Material Type:
Article
Add to My Research

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer

Molecular oncology, 2023-05, Vol.17 (5), p.747-764 [Peer Reviewed Journal]

2022 The Authors. published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. ;2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. ;COPYRIGHT 2023 John Wiley & Sons, Inc. ;2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1574-7891 ;EISSN: 1878-0261 ;DOI: 10.1002/1878-0261.13342 ;PMID: 36423211

Full text available

Results 1 - 20 of 9,189  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (9,098)

Refine My Results

Creation Date 

From To
  1. Before 1974  (30)
  2. 1974 To 1985  (78)
  3. 1986 To 1997  (205)
  4. 1998 To 2010  (981)
  5. After 2010  (7,896)
  6. More options open sub menu

Resource Type 

  1. Articles  (9,170)
  2. Reports  (15)
  3. Book Chapters  (4)
  4. More options open sub menu

Subject 

  1. Science & Technology  (8,033)
  2. Life Sciences & Biomedicine  (7,953)
  3. Humans  (6,006)
  4. Male  (3,046)
  5. General & Internal Medicine  (2,984)
  6. Medicine, General & Internal  (2,981)
  7. Lung Cancer  (2,920)
  8. Female  (2,828)
  9. Middle Aged  (2,090)
  10. Aged  (1,656)
  11. Adult  (1,402)
  12. Original  (1,393)
  13. Animals  (1,348)
  14. Lung Neoplasms - Pathology  (1,282)
  15. Tumors  (1,228)
  16. Patients  (1,155)
  17. Oncology  (1,087)
  18. Proteins  (1,004)
  19. Lung Diseases  (955)
  20. Prognosis  (938)
  21. More options open sub menu

Language 

  1. English  (9,174)
  2. Japanese  (831)
  3. Chinese  (18)
  4. Norwegian  (10)
  5. Italian  (3)
  6. French  (1)
  7. German  (1)
  8. More options open sub menu

Searching Remote Databases, Please Wait